Dr. Tan Ince Named Chief of Pathology at NewYork-Presbyterian Brooklyn Methodist Hospital
Jan 7, 2020
Dr. Tan A. Ince has been named chief of pathology at NewYork-Presbyterian Brooklyn Methodist Hospital, effective February 1. Dr. Ince was also recruited to Weill Cornell Medicine as a professor of pathology and laboratory medicine.
Dr. Ince will lead NewYork-Presbyterian Brooklyn Methodist’s pathology enterprise, which provides cutting-edge clinical and laboratory services and engages in translational research. He also plans to build a biospecimen repository, where patient samples can be consented, stored and sampled properly to aid in translational research and precision medicine. Dr. Ince will also mentor the next generation of pathologists and cultivate a supportive environment for pathologists early in their careers.
Dr. Ince joins NewYork-Presbyterian Brooklyn Methodist Hospital and Weill Cornell Medicine from the University of Miami, where he served as professor of pathology at the Miller School of Medicine for the past decade.
“We are delighted to welcome Dr. Ince to NewYork-Presbyterian Brooklyn Methodist Hospital to lead our pathology efforts,” said Robert Guimento, president of NewYork-Presbyterian Brooklyn Methodist Hospital. “Pathology touches every aspect of medicine, and Dr. Ince’s exceptional skill as a physician, researcher and educator will make a tremendous contribution to our institution and our patients.”
“An esteemed physician-scientist, Dr. Ince’s expertise in the field of pathology will help us illuminate the causes of disease and translate that research into the best care for our patients,” said Dr. Massimo Loda, chair of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine and pathologist-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center. “Dr. Ince will be an invaluable addition to Weill Cornell Medicine and NewYork-Presbyterian, and we are pleased welcome him.”
A leading physician-scientist, Dr. Ince has a background in molecular oncology, cancer pharmacology and clinical pathology. His research has focused on gynecologic and breast cancers, and he has recently expanded his research to study the development of leukemias and sarcomas. He received a grant from the National Institutes of Health (NIH) to develop a patient-derived cell culture technology for precision medicine application.
“I am pleased to be joining NewYork-Presbyterian Brooklyn Methodist Hospital and Weill Cornell Medicine, whose reputations as innovative leaders are unparalleled,” said Dr. Ince. “Pathology must take a leading role in the implementation of precision medicine, and it’s an exciting time to be a part of this new frontier of medicine, which will change the way we treat patients.”
At the University of Miami and Miller School of Medicine, Dr. Ince served as the director of Tumor Stem Cell Division at its Interdisciplinary Stem Institute, and also established the Live Tissue Culture Service Center to provide his cell culture technology inventions to the research community. The center has delivered cell cultures and nutrient media invented by Dr. Ince to 100 laboratories in 15 countries. Prior to that, he held appointments at Brigham and Women’s Hospital, Harvard Medical School and Whitehead Institute.
Dr. Ince received his medical degree from Hacettepe University School of Medicine in Ankara, Turkey and his doctorate in pharmacology from the Weill Cornell Graduate School of Medical Sciences. He completed a residency in anatomic pathology at Massachusetts General Hospital and Harvard Medical School, followed by a fellowship in women’s and perinatal pathology at Brigham and Women’s Hospital and Harvard, and post-doctoral fellowship at Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology.
Dr. Ince is a member of the Center for Genomic Pathology, the American Association for Cancer Research, the American Association for the Advancement of Science, The Harvey Society and the New York Academy of Sciences. Dr. Ince is the author of more than 60 papers and holds several patents relating to cell culture and tissue culture technologies.
Office of Communications 212-821-0667 [email protected]